CL2017002314A1 - Métodos de preparación de polinucleótidos usando composiciones salinas de cationes multivalentes - Google Patents
Métodos de preparación de polinucleótidos usando composiciones salinas de cationes multivalentesInfo
- Publication number
- CL2017002314A1 CL2017002314A1 CL2017002314A CL2017002314A CL2017002314A1 CL 2017002314 A1 CL2017002314 A1 CL 2017002314A1 CL 2017002314 A CL2017002314 A CL 2017002314A CL 2017002314 A CL2017002314 A CL 2017002314A CL 2017002314 A1 CL2017002314 A1 CL 2017002314A1
- Authority
- CL
- Chile
- Prior art keywords
- polynucleotide
- salt
- composition
- methods
- multivalent cations
- Prior art date
Links
- 102000040430 polynucleotide Human genes 0.000 title abstract 13
- 108091033319 polynucleotide Proteins 0.000 title abstract 13
- 239000002157 polynucleotide Substances 0.000 title abstract 13
- 150000003839 salts Chemical class 0.000 title abstract 7
- 239000000203 mixture Substances 0.000 title abstract 6
- 238000000034 method Methods 0.000 title abstract 4
- 150000001768 cations Chemical class 0.000 title abstract 3
- 239000002777 nucleoside Substances 0.000 abstract 2
- 150000003833 nucleoside derivatives Chemical class 0.000 abstract 2
- -1 cation salt Chemical class 0.000 abstract 1
- 239000003153 chemical reaction reagent Substances 0.000 abstract 1
- 238000004587 chromatography analysis Methods 0.000 abstract 1
- 150000002500 ions Chemical class 0.000 abstract 1
- 238000004366 reverse phase liquid chromatography Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1003—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1003—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor
- C12N15/1006—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor by means of a solid support carrier, e.g. particles, polymers
- C12N15/101—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor by means of a solid support carrier, e.g. particles, polymers by chromatography, e.g. electrophoresis, ion-exchange, reverse phase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P19/00—Preparation of compounds containing saccharide radicals
- C12P19/26—Preparation of nitrogen-containing carbohydrates
- C12P19/28—N-glycosides
- C12P19/30—Nucleotides
- C12P19/34—Polynucleotides, e.g. nucleic acids, oligoribonucleotides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6806—Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
- C12N2310/113—Antisense targeting other non-coding nucleic acids, e.g. antagomirs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/314—Phosphoramidates
- C12N2310/3145—Phosphoramidates with the nitrogen in 3' or 5'-position
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3515—Lipophilic moiety, e.g. cholesterol
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
- C12Y207/07—Nucleotidyltransferases (2.7.7)
- C12Y207/07049—RNA-directed DNA polymerase (2.7.7.49), i.e. telomerase or reverse-transcriptase
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Analytical Chemistry (AREA)
- Crystallography & Structural Chemistry (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Treatment Of Liquids With Adsorbents In General (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
<p>Los aspectos de la descripción incluyen métodos para la preparación de un polinucleótido. En algunas modalidades, el método incluye poner en contacto una primera composición de polinucleótidos que incluye: un polinucleótido que tiene una secuencia de 7 o más subunidades nucleósido donde al menos dos de las subunidades nucleósido están unidas por un enlace entre subunidades de tiofosforamidato N3'→P5'; y reactivos y productos sintéticos no objetivo; con una sal de cationes multivalente para precipitar una primera sal de polinucleótidos que incluye al menos un contraión de cationes multivalente; y separar la sal de polinucleótidos de la primera composición de polinucleótidos en contacto para producir una segunda composición de polinucleótidos que incluye la primera sal de polinucleótidos. En determinadas modalidades, el método incluye además poner en contacto la primera sal de polinucleótidos con un soporte de cromatografía de fase inversa; y eluir a partir del soporte de cromatografía una tercera composición de polinucleótidos que incluye una segunda sal de polinucleótidos. También se proporcionan composiciones que incluyen una sal del polinucleótido que incluye al menos un contraión de cationes multivalentes.</p>
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562151891P | 2015-04-23 | 2015-04-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2017002314A1 true CL2017002314A1 (es) | 2018-05-04 |
Family
ID=55911083
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2017002314A CL2017002314A1 (es) | 2015-04-23 | 2017-09-13 | Métodos de preparación de polinucleótidos usando composiciones salinas de cationes multivalentes |
Country Status (36)
| Country | Link |
|---|---|
| US (2) | US10745687B2 (es) |
| EP (1) | EP3286203B1 (es) |
| JP (4) | JP2018513127A (es) |
| KR (1) | KR102401252B1 (es) |
| CN (2) | CN113564168B (es) |
| AU (2) | AU2016250576C1 (es) |
| BR (1) | BR112017019627B1 (es) |
| CA (1) | CA2978191C (es) |
| CL (1) | CL2017002314A1 (es) |
| CO (1) | CO2017009217A2 (es) |
| CY (1) | CY1123197T1 (es) |
| DK (1) | DK3286203T3 (es) |
| EA (1) | EA035885B1 (es) |
| ES (1) | ES2798270T3 (es) |
| HR (1) | HRP20201218T1 (es) |
| HU (1) | HUE051148T2 (es) |
| IL (1) | IL254222A0 (es) |
| LT (1) | LT3286203T (es) |
| MA (2) | MA42157A (es) |
| MD (1) | MD3286203T2 (es) |
| ME (1) | ME03811B (es) |
| MX (1) | MX383293B (es) |
| MY (1) | MY187804A (es) |
| PE (2) | PE20171785A1 (es) |
| PH (1) | PH12017501927B1 (es) |
| PT (1) | PT3286203T (es) |
| RS (1) | RS60645B1 (es) |
| SA (1) | SA517390103B1 (es) |
| SG (2) | SG11201707893RA (es) |
| SI (1) | SI3286203T1 (es) |
| SM (1) | SMT202000389T1 (es) |
| TN (1) | TN2017000411A1 (es) |
| TW (1) | TWI736532B (es) |
| UA (1) | UA124521C2 (es) |
| WO (1) | WO2016172346A1 (es) |
| ZA (1) | ZA201706041B (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA035885B1 (ru) | 2015-04-23 | 2020-08-27 | Джерон Корпорейшн | Способы получения полинуклеотидов с использованием композиций солей поливалентных катионов |
| CA3003090A1 (en) | 2015-10-22 | 2017-04-27 | Modernatx, Inc. | Cancer vaccines |
| WO2018111967A1 (en) | 2016-12-13 | 2018-06-21 | Modernatx, Inc. | Rna affinity purification |
| JP7048617B2 (ja) | 2016-12-19 | 2022-04-05 | ヴェンタナ メディカル システムズ, インク. | ペプチド核酸コンジュゲート |
| MA49914A (fr) * | 2017-08-18 | 2021-04-21 | Modernatx Inc | Procédés analytiques par hplc |
| WO2019060522A2 (en) * | 2017-09-22 | 2019-03-28 | The Regents Of The University Of Colorado, A Body Corporate | OLIGONUCLEOTIDES THIOMORPHOLINO FOR THE TREATMENT OF MUSCLE DYSTROPHY |
| WO2019120635A1 (en) | 2017-12-18 | 2019-06-27 | Ventana Medical Systems, Inc. | Peptide nucleic acid conjugates |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4046720A (en) | 1974-01-17 | 1977-09-06 | California Institute Of Technology | Crosslinked, porous, polyacrylate beads |
| US4413070A (en) | 1981-03-30 | 1983-11-01 | California Institute Of Technology | Polyacrolein microspheres |
| US4678814A (en) | 1981-03-30 | 1987-07-07 | California Institute Of Technology | Polyacrolein microspheres |
| US5185444A (en) | 1985-03-15 | 1993-02-09 | Anti-Gene Deveopment Group | Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages |
| US4659774A (en) | 1985-11-01 | 1987-04-21 | American Hoechst Corporation | Support for solid-phase oligonucleotide synthesis |
| EP0546055B1 (en) | 1990-08-31 | 1996-07-10 | Regents Of The University Of Minnesota | Polyethylene glycol derivatives for solid-phase applications |
| US5281701A (en) | 1991-07-12 | 1994-01-25 | Applied Biosystems, Inc. | Process and compounds for RNA synthesis |
| US5476925A (en) | 1993-02-01 | 1995-12-19 | Northwestern University | Oligodeoxyribonucleotides including 3'-aminonucleoside-phosphoramidate linkages and terminal 3'-amino groups |
| US5726297A (en) | 1994-03-18 | 1998-03-10 | Lynx Therapeutics, Inc. | Oligodeoxyribonucleotide N3' P5' phosphoramidates |
| CZ274596A3 (en) | 1994-03-18 | 1997-03-12 | Lynx Therapeutics | Oligonucleotide n3 - p5 phosphoramidates and process of their synthesis and hybridization |
| US5599922A (en) | 1994-03-18 | 1997-02-04 | Lynx Therapeutics, Inc. | Oligonucleotide N3'-P5' phosphoramidates: hybridization and nuclease resistance properties |
| US5684143A (en) | 1996-02-21 | 1997-11-04 | Lynx Therapeutics, Inc. | Oligo-2'-fluoronucleotide N3'->P5' phosphoramidates |
| US5859233A (en) | 1996-02-21 | 1999-01-12 | Lynx Therapeutics, Inc. | Synthons for synthesis of oligonucleotide N3-P5 phosphoramidates |
| JP2001507229A (ja) | 1996-12-20 | 2001-06-05 | ジェロン コーポレイション | テロメラーゼのrna成分を検出および阻害するための方法 |
| US5998604A (en) | 1997-09-15 | 1999-12-07 | The Perkin-Elmer Corporation | Polynucleotide purification method |
| US6114519A (en) | 1997-10-15 | 2000-09-05 | Isis Pharmaceuticals, Inc. | Synthesis of sulfurized oligonucleotides |
| US6465628B1 (en) | 1999-02-04 | 2002-10-15 | Isis Pharmaceuticals, Inc. | Process for the synthesis of oligomeric compounds |
| KR100858465B1 (ko) | 1999-09-10 | 2008-09-16 | 제론 코포레이션 | 올리고뉴클레오티드 엔3'→피5' 티오포스포라미데이트,이의 합성 및 용도 |
| JP2002060341A (ja) * | 2000-08-21 | 2002-02-26 | Terumo Corp | 止血剤 |
| EP1379689B1 (en) | 2001-03-23 | 2012-09-26 | Geron Corporation | Oligonucleotide conjugates |
| US7563618B2 (en) | 2001-03-23 | 2009-07-21 | Geron Corporation | Oligonucleotide conjugates |
| US20120329858A1 (en) | 2010-08-04 | 2012-12-27 | Geron Corporation | Modified oligonucleotides for telomerase inhibition |
| JP4690324B2 (ja) * | 2003-09-09 | 2011-06-01 | ジェロン・コーポレーション | テロメラーゼ阻害のための改変オリゴヌクレオチド |
| TW200540180A (en) | 2004-05-28 | 2005-12-16 | Sankyo Co | Telomerase inhibitor ena oligonucleotide |
| SI3296312T1 (sl) | 2004-07-02 | 2021-08-31 | Geron Corporation | Sinteza zaščitenih 3'-amino 5'-fosforamiditnih nukleozidnih monomerov |
| CN103215248B (zh) * | 2005-10-03 | 2016-05-18 | 应用生物系统有限责任公司 | 用于扩增核酸的组合物、方法和试剂盒 |
| US9109015B2 (en) * | 2006-11-01 | 2015-08-18 | Biogen Ma Inc | Method of isolating biomacromolecules using low pH and divalent cations |
| SI2605794T1 (sl) * | 2010-08-20 | 2017-01-31 | Replicor Inc. | Oligonukleotidni kelatni kompleksi |
| US9106103B2 (en) | 2011-09-23 | 2015-08-11 | Eaton Corporation | Unintteruptible power supply systems and methods employing on-demand energy storage |
| US9006630B2 (en) | 2012-01-13 | 2015-04-14 | Altasens, Inc. | Quality of optically black reference pixels in CMOS iSoCs |
| AR091065A1 (es) | 2012-05-18 | 2014-12-30 | Replicor Inc | Una formulacion farmaceutica que comprende un quelato de oligonucleotidos antiviral para el tratamiento de una infeccion antiviral |
| KR102264617B1 (ko) * | 2012-06-14 | 2021-06-14 | 라이프 테크놀로지스 코포레이션 | 폴리머라제 연쇄 반응 (pcr)을 위한 신규 조성물, 방법 및 키트 |
| MY180634A (en) | 2012-12-07 | 2020-12-03 | Geron Corp | Use of telomerase inhibitors for the treatment of myeloproliferative disorders and myeloproliferative neoplasms |
| JOP20200257A1 (ar) | 2014-05-01 | 2017-06-16 | Geron Corp | تركيبات أوليجو نوكليوتيد وطرق لتحضيرها |
| EA035885B1 (ru) | 2015-04-23 | 2020-08-27 | Джерон Корпорейшн | Способы получения полинуклеотидов с использованием композиций солей поливалентных катионов |
-
2016
- 2016-04-21 EA EA201791753A patent/EA035885B1/ru unknown
- 2016-04-21 US US15/134,740 patent/US10745687B2/en active Active
- 2016-04-21 CN CN202110878917.1A patent/CN113564168B/zh active Active
- 2016-04-21 MY MYPI2017703910A patent/MY187804A/en unknown
- 2016-04-21 HR HRP20201218TT patent/HRP20201218T1/hr unknown
- 2016-04-21 TW TW105112455A patent/TWI736532B/zh active
- 2016-04-21 BR BR112017019627-1A patent/BR112017019627B1/pt active IP Right Grant
- 2016-04-21 PH PH1/2017/501927A patent/PH12017501927B1/en unknown
- 2016-04-21 SG SG11201707893RA patent/SG11201707893RA/en unknown
- 2016-04-21 SG SG10201909816P patent/SG10201909816PA/en unknown
- 2016-04-21 EP EP16720636.6A patent/EP3286203B1/en active Active
- 2016-04-21 MA MA042157A patent/MA42157A/fr unknown
- 2016-04-21 DK DK16720636.6T patent/DK3286203T3/da active
- 2016-04-21 WO PCT/US2016/028657 patent/WO2016172346A1/en not_active Ceased
- 2016-04-21 AU AU2016250576A patent/AU2016250576C1/en active Active
- 2016-04-21 ES ES16720636T patent/ES2798270T3/es active Active
- 2016-04-21 ME MEP-2020-161A patent/ME03811B/me unknown
- 2016-04-21 TN TNP/2017/000411A patent/TN2017000411A1/en unknown
- 2016-04-21 JP JP2017548279A patent/JP2018513127A/ja not_active Withdrawn
- 2016-04-21 LT LTEP16720636.6T patent/LT3286203T/lt unknown
- 2016-04-21 SM SM20200389T patent/SMT202000389T1/it unknown
- 2016-04-21 CN CN201680014382.0A patent/CN107429247B/zh active Active
- 2016-04-21 MX MX2017011642A patent/MX383293B/es unknown
- 2016-04-21 MA MA42569A patent/MA42569B1/fr unknown
- 2016-04-21 UA UAA201708890A patent/UA124521C2/uk unknown
- 2016-04-21 PE PE2017001516A patent/PE20171785A1/es unknown
- 2016-04-21 PT PT167206366T patent/PT3286203T/pt unknown
- 2016-04-21 KR KR1020177025835A patent/KR102401252B1/ko active Active
- 2016-04-21 HU HUE16720636A patent/HUE051148T2/hu unknown
- 2016-04-21 SI SI201630771T patent/SI3286203T1/sl unknown
- 2016-04-21 PE PE2022001164A patent/PE20221275A1/es unknown
- 2016-04-21 MD MDE20180204T patent/MD3286203T2/ro unknown
- 2016-04-21 CA CA2978191A patent/CA2978191C/en active Active
- 2016-04-21 RS RS20200935A patent/RS60645B1/sr unknown
-
2017
- 2017-08-30 IL IL254222A patent/IL254222A0/en active IP Right Grant
- 2017-09-05 ZA ZA201706041A patent/ZA201706041B/en unknown
- 2017-09-12 CO CONC2017/0009217A patent/CO2017009217A2/es unknown
- 2017-09-13 CL CL2017002314A patent/CL2017002314A1/es unknown
- 2017-10-04 SA SA517390103A patent/SA517390103B1/ar unknown
-
2020
- 2020-07-09 CY CY20201100632T patent/CY1123197T1/el unknown
- 2020-07-10 US US16/926,340 patent/US11441144B2/en active Active
-
2021
- 2021-05-04 AU AU2021202803A patent/AU2021202803A1/en not_active Abandoned
- 2021-07-01 JP JP2021110090A patent/JP2021152079A/ja active Pending
-
2022
- 2022-09-02 JP JP2022140111A patent/JP2022168017A/ja not_active Withdrawn
-
2025
- 2025-01-27 JP JP2025011546A patent/JP2025061848A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2017002314A1 (es) | Métodos de preparación de polinucleótidos usando composiciones salinas de cationes multivalentes | |
| CO2017011957A2 (es) | Variantes de alfa-amilasa y polinucleótidos que codifican las mismas | |
| CL2016002010A1 (es) | Métodos y sistemas para generar mapas colaborativos compartidos | |
| MX2017015046A (es) | Anticuerpos anti-antigeno 4 del linfocito t citotoxico (ctla-4) y metodos para uso de los mismos. | |
| CY1122175T1 (el) | Δομες πολυειδικου αντισωματος | |
| MX386500B (es) | Anticuerpos contra icos | |
| CO2018002196A2 (es) | Proteínas de fusión de factor ix y métodos para producirlas y utilizarlas | |
| MX2018005551A (es) | Anticuerpos que se unen especificamente a pd-1, y sus usos. | |
| BR112014009066B8 (pt) | molécula de ácido nucleico, método para a sintetização de uma molécula de dna de triciclo-fosforotioato e composição farmacêutica | |
| CL2018001770A1 (es) | Composiciones de decil mercaptanos mezclados y uso de las mismas como colectoras de productos químicos de minería | |
| AR110677A1 (es) | Anticuerpos anti-c1s y métodos para usarlos | |
| BR112016006916A2 (pt) | lâmina estacionária para um conjunto de lâmina de um aparelho de corte de pelos, conjunto de lâmina para um aparelho de corte de pelos, e, aparelho de corte de pelos | |
| MX2019007248A (es) | Enzimas de polimerizacion para reacciones de secuenciacion. | |
| BR112017007411A2 (pt) | método em a máquina de plantio de mudas e máquina de plantio de mudas | |
| BR112017000135B8 (pt) | Processo para a preparação de ácidos 4-alcóxi-3-hidroxipicolínico | |
| MX2018006489A (es) | Nanoemulsiones para bebidas producidas mediante un proceso de alto cizallamiento. | |
| BR112016025196A2 (pt) | composições de oligonucleotídeo e métodos de fazê-las | |
| BR112016015820A2 (pt) | Transformante para expressar cis-preniltransferase e receptor nogo b | |
| BR112014015288A2 (pt) | máquina e processo para tornear pelo menos ressaltos planos de um eixo de manivela que circunda pinos de manivela | |
| BR112019001409A2 (pt) | células renais bioativas para o tratamento de doença renal crônica | |
| MX2017013143A (es) | Uso de acido alcanosulfonico para limpieza en las industrias azucareras. | |
| DOP2015000294A (es) | Preparado farmacéutico | |
| BR112016024466A2 (pt) | método para a síntese de clofarabina | |
| BR112018074079A2 (pt) | unidade de produção de sumo que tem um apoio | |
| CY1122334T1 (el) | Νεες κρυσταλλικες mopφeς του αλατος μονονατριου της φορμασουλφουρονης |